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ABSTRACT 
 
 
Every year millions of people contract HIV or die from HIV-AIDS related 
illnesses.  Since current drugs generally target viral enzymes, selective drug pressure 
coupled with the high mutation rate and infidelity of HIV-1 reverse transcriptase lead to 
drug resistance.  It is thus crucial to develop new, tighter-binding inhibitors with more 
flexible structures that can better inhibit mutant proteases.  Two novel inhibitor cores 
were designed and synthesized, all while attempting to stay within the confines of the 
substrate-envelope.  Many new drugs were tested, which bound to various drug-resistant 
mutants in the pM range. 
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BACKGROUND 
 
 
 
Human Immunodeficiency Virus Pandemic 
The Human Immunodeficiency Virus (HIV) is a single-stranded positive-sense 
RNA retrovirus that is further classified as a lentivirus.  Lentiviruses infect and replicate 
in non-dividing cells, in which HIV mainly infects CD4
+
 T cells, but have also been 
known to infect macrophages and dendritic cells (Weiss, 1993).   
HIV has been considered a pandemic for the past 30 years.  The time between 
initial infection and the time it takes for serious symptoms to occur is very long for 
lentiviruses, which is why many people are unaware that they are infected, and 
unfortunately spread the disease unknowingly (NIAID’s).  Infection eventually leads 
patients to develop Acquired Immunodeficiency Syndrome (AIDS), in which an 
individual’s immune system is so low that any opportunistic infection can potentially lead 
to death.  Since the beginning of the epidemic, the number of AIDS-related deaths has 
been estimated to be over 25 million, with 1.8 million in 2009 alone.  Around 60 million 
people have been infected with HIV, and there are an estimated 33.3 million people who 
are currently infected with HIV (UNAIDS).   
 
The HIV-1 Genome and Structure 
The HIV virion is a spherical virus with a diameter of 100 nm and its outer coat, 
or viral envelope is made up of a lipid bilayer that was budded from the host cell, and 
around 72 HIV Env proteins.  The Env proteins consist of surface tri-mers of gp120/SU 
and tri-mers of transmembrane gp41/TM proteins.  Lining the inside of the viral envelope 
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is the matrix (MA or p17) proteins.  Within this matrix there are around 1,056 capsid (CA 
or p24) proteins that surround two identical full-length copies of HIV RNA (NIAID’s; 
Pornillos et al., 2011).  Each RNA strand is around 9-kb long, flanked on both sides by 
long terminal repeats (LTR’s) which control the production of new viruses by either 
proteins from the virus or the host cell.  In order to protect the genomic RNA inside the 
virion core, there are nucleocapsid (NC or p7) proteins which nonspecifically bind to 
nucleic acids, thus protecting the RNA from nucleases and also compacts it within the 
core.  There are three Pol proteins which are essential enzymes that are also encapsulated 
within the capsid; they are protease (PR), reverse transcriptase (RT), and integrase (IN).  
Along with these eight proteins, there is a p6 protein also located within the virion, as 
well as six accessory proteins.  Three of the six proteins (Vif, Vpr, and Nef) are found 
within the viral particle, while (Tat, Rev, and Vpu) are not (Frankel and Young, 1998).  
Figure 1 shows both the organization of the HIV-1 genome and the general structure of 
the virion. 
 
                                 Figure 1: HIV-1 Genome and Structure (Frankel and Young, 1998). 
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As seen in Figure 1, the HIV-1 genome has nine open reading frames (ORF’s) that 
encode 15 different proteins.  Three of these ORF’s encode the Gag, Pol, and Env 
polyproteins, which are the main viral proteins.  These polyproteins are then cleaved by 
the protease as to separate the individual proteins.  Gag is cleaved into the four following 
proteins: MA, CA, NC, and p6; Pol is cleaved into three enzymes: PR, RT, and IN, and 
Env is cleaved into SU and TM proteins (Frankel and Young, 1998).  There is a small 
spacer peptide (p1) between NC and p6, and between CA and NC there is another small 
spacer peptide (p2). These spacers help regulate the rate and location of PR cleavage 
(Freed, 1998).  The six other proteins are essentially accessory proteins and are encoded 
individually; they are: Vif, Vpr, Nef, Tat, Rev, and Vpu (Frankel and Young, 1998).   
 
The Lifecycle of HIV-1 
Cells become infected with HIV when the glycoprotein gp120 of a mature virion 
binds CD4 and interacts with one of two chemokine co-receptors, CCR-5 or CXCR-4.  
These co-receptors are crucial, because both virus adsorption and cellular infectivity 
increase for cells which have low amounts of CD4 but high amounts of one of the co-
receptors (Kozak et al., 1997).  The transmembrane glycoprotein gp41 undergoes a 
conformational change, which promotes fusion between the virion and the host cell, 
ultimately releasing the viral capsid within the host cell.  The viral capsid is then 
uncoated and the viral ss-RNA is converted to ds-DNA by the viral RT enzyme.  The 
viral DNA enters the nucleus and is incorporated into the chromosomal DNA by the IN 
enzyme (Freed, 1998).  The viral genes are then expressed, in which Tat greatly increases 
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the rate of viral transcription.  Most of the mRNA’s are translated in the cytoplasm, 
except for the Env mRNA which is translated in the endoplasmic reticulum (ER).  Full-
length viral RNA’s are spliced and transported to the cytoplasm, to be translated or 
packaged, and is regulated by Rev.  Vpu promotes the degradation of CD4 which is 
coexpressed with Env in the ER, while Nef degrades surface CD4 so that Env can be 
transported to the cell surface.  The viral proteins and RNA are assembled at the cell 
surface and an immature virion buds from the cell, with its cell surface coated by both 
gp120 and gp41.  The viral PR cleaves the Gag and Gag-Pol polyproteins into their 
mature active proteins, thus becoming a mature virion (Frankel and Young, 1998).  If this 
final proteolytic step does not occur, then newly budded viral particles are noninfectious 
(Warnke and Barreto, 2007).  For this reason, HIV-1 PR is one of the main therapeutic 
targets for developing anti-HIV-1 drugs. 
 
Anti-retroviral Drugs Used to Treat HIV 
There are currently six different classes of antiretroviral drugs that are FDA-
approved for treating HIV infections.  These classes are nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors (FIs), entry inhibitors/co-receptor inhibitors (CRIs), and 
integrase inhibitors (INIs), in which the latter three only consist of one drug per class.  
Each class of drug combats the HIV virus differently, but all do so during the most 
crucial steps in the viral life-cycle (Mehellou and De Clercq, 2010).  Table 1 shows the 
six different drug classes and the approved drugs within each class.  
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               Table 1: FDA-Approved Antiretroviral Drugs Used in the Treatment of HIV Infection. 
Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
Non-
Nucleoside  
Reverse 
Transcriptase 
Inhibitors 
Protease 
Inhibitors 
Fusion 
Inhibitors 
Entry Inhibitors- 
CCR5  
co-receptor 
antagonist 
HIV Integrase 
strand 
transfer 
Inhibitors 
Combivir Intelence Amprenavir Fuzeon Selzentry Isentress 
Emtriva Rescriptor Tipranavir 
   Epivir Sustiva Indinavir 
 
  Epzicom Viramune Saquinavir 
   Hivid 
 
Lopinavir 
   Retrovir 
 
Ritonavir 
   Trizivir 
 
Darunavir 
   Truvada 
 
Atazanavir 
   Videx 
 
Nelfinavir 
   Viread 
     Zerit 
     Ziagen 
      
The first approved drug class was the NRTIs, with the first drug being approved 
in 1987.  This drug class inhibits the HIV reverse transcriptase because the molecules get 
incorporated into the growing DNA strand but lack a 3’-hydroxyl group, thus preventing 
incoming nucleotides from forming a phosphodiester bond.  These drugs actively 
compete with natural nucleotides so their addition terminates the growing DNA strand 
and renders it useless.  The problem with these drugs is that in order to work, they first 
must be phosphorylated to their active 5’ triphosphate form by using cellular kinases, so 
they may not become phosphorylated (Warnke and Barreto, 2007). 
The second class of anti-HIV drugs are NNRTIs, and work by noncompetitively 
binding close to the active site of reverse transcriptase which causes a conformational 
change of the active site (Warnke and Barreto, 2007).   
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Two drugs inhibit the entry of the virion into the host cell and are classified as an 
FI and a CRI.  These drugs block the virion’s glycoproteins from fusing with a host cell.  
There is only one INI, and it stops the viral DNA from incorporating itself into cellular 
DNA.  Protease inhibitors are competitive inhibitors to the different substrates that HIV-1 
protease cleaves.  These PIs are non-cleavable molecules; hence the protease cannot 
cleave the polyproteins into their individual and active proteins (Mehellou and De Clercq, 
2010).   
 
HIV-1 Protease 
The active HIV-1 protease (PR) is a homo-dimer, in which the active site is 
formed between two 99-residue monomers, each monomer contributes a catalytically 
essential aspartic acid (Asp25/Asp25’) (Frankel and Young, 1998).  HIV PR is similar to 
other aspartyl proteases, in which a proton from a water molecule is transferred to one of 
the aspartic acids, followed by the transfer of a proton from the other aspartic acid to the 
peptide bond which is being cleaved, and briefly creates a tetrahedral non-covalent 
transition state.  Another important feature of the protease is the presence of a conserved 
water molecule within the binding pocket, which mediates contacts between the amide 
groups of Ile50/Ile50’ and the P2/P1 and P2’/P1’ carbonyl oxygen atoms (Ali et al., 
2010).  In order for PR to bind the substrate, the two mobile flaps of the PR must move 
away, and once the substrate is bound, they move back over the active site and lock down 
over the bound substrate (Anderson et al., 2009).  The PR cleaves the Gag and Gag-Pol 
polyproteins at 12 different sites (Figure 2) (Perez et al., 2010). 
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Figure 2. A schematic representation of the 12 substrate cleavage sites within the HIV-1 
polyproteins (Perez et al., 2010). 
 
 
HIV-1 Protease Substrate Cleavage Sites 
The PR enzyme recognizes 12 sequences of eight amino acids (P4-P4’), which are 
quite diverse, and then cleaves the scissile bond between P1 and P1’, which is denoted by 
an asterisk in Table 2 (Perez et al., 2010).  Most of the substrate sites have a branched 
amino acid residue at the P2 site, a hydrophobic residue at P1, and either an aromatic or 
proline at P1’.  Due to this variance, the enzyme cleaves different substrates with 
efficiencies that differ by nearly 400-fold (Anderson et al., 2009).  One of the fastest 
substrates to be cleaved is the first one, which is cleaved at the Tyr-Pro peptide bond.  
This reaction yields a Km of around 103 µM, and a turnover number (kcat) of 4.9 s
-1
 
(Matayoshi et al., 1990). 
                                           Table 2. The 12 Sequences Cleaved by HIV-1 Protease. 
Substrate Sequences 
(P4-P4')  
Cleavage 
Domain 
SQNY*PIVQ  MA-CA 
ARVL*AEAM  CA-p2 
ATIM*MQRG  p2-NC 
RQAN*FLGK  NC-p1 
RQAN*FLRE  NC-TFP 
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PGNF*LQSR p1-p6gag 
DLAF*LQGK  TFP-p6pol 
SFNF*PQVT  p6pol-PR 
TLNF*PISP  PR-RTp51 
AETF*YVDG RTp51-RTp66 
RKVL*FLDG  RTp66-INT 
DCAW*LEAQ NEF 
 
HIV-1 Protease Inhibitors 
There are nine FDA-approved HIV-1 PIs (Figure 3), and all are competitive 
active site inhibitors which bind the wild-type (Q7K) protease from the nanomolar to 
picomolar range.  All but TPV are peptidomimetics which mimic the enzymatic transition 
state, with several different non-cleavable scaffold cores (Anderson et al., 2009).  These 
PIs are generally hydrophobic and interact with the mainly hydrophobic S2-S2’ pockets 
in the PR active site.  Although the PIs are chemically different, their three-dimensional 
shapes and electrostatic characteristics are quite similar (Nalam and Schiffer, 2008).  
There are either six or seven bonds between the two critical P2/P1’ carbonyl oxygen 
atoms, which is very similar to the six bonds between the substrates.  For the 
peptidomimetic PIs there also is a secondary hydroxyl group in place of the carbonyl at 
P1, which interact with the catalytic Asp25/25’ protease residues and is necessary for 
tight PI binding (Ali et al., 2010).   Darunavir is the most potent PI (Anderson et al., 
2009) and has both six bonds between the two carbonyls along with the secondary non-
cleavable hydroxyl group at P1, making DRV a great reference when developing new 
PIs.    
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Figure 3. FDA-approved HIV-1 protease inhibitors, with the different scaffold cores 
shown in color (Ali et al. 2010). 
 
 
Development of HIV-1 Drug-Resistant Protease Variants 
The main reasons for drug-resistant mutations in HIV-1 PR are due to the high 
mutation rate and infidelity of HIV-1 RT and to selective drug pressure (King et al., 
2004).  HIV-1 replicates in and infects new cells at an extremely high rate, and since the 
RT does not have any proofreading ability, the process is error-prone.  About one 
mutation occurs per transcribed viral genome.  Most are base substitutions, but others are 
duplications, insertions, and recombinations (Clavel and Hance, 2004).  When patients 
undergo antiretroviral therapy, observed mutations occur more frequently because the 
virus must evolve to survive.  Once a primary drug-mutation occurs by introducing a PI, 
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secondary mutations often occur, which help increase the fitness of the protease (Nalam 
and Schiffer, 2008). 
Mutations of the PR occur at residues both inside and outside the active site, and 
at least 34 of the 99 residues of each monomer show that mutations have clinical 
significance.  The HIV-1 protease genome of most highly advanced patients usually has 
between five and 15 mutations.  Some of the most common active site mutations are 
D30N, G48V, V82A, I84V, I50V, and I50L, with I84V being the worst of the multi-drug-
resistant mutations as it strongly impacts the binding of most PIs (Nalam and Schiffer, 
2008; King et al., 2004).  The I50V, V82A, and I84V mutations all decrease the residue 
size, thus losing on average two or more crucial van der Waals contacts between the PR 
and the PI as compared between the normal wild-type PR and the substrate (King et al., 
2004).  Mutations outside the active site cause a large conformational change of the PR to 
process and release its substrate, but PIs are less dynamic because they should stay tightly 
bound to the PR.  Increasing the flexibility of the PR detrimentally affects inhibitor 
binding by increasing the rate of dissociation between the PR and the PI (Nalam and 
Schiffer, 2008). 
 
Substrate Envelope Hypothesis 
Although the normal PR protein substrates are quite different structurally, various 
cleavage site peptides adopt a conserved shape/volume.  By overlapping the volumes of 
various bound substrates within the active site, a conserved shape has been identified 
called the substrate envelope (Figure 4A).  This method can also be done with the PIs 
bound to wild-type PR, because they too adopt a conserved shape and contact similar 
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residues within the active site of the PR, and is called the inhibitor envelope (Figure 4B).  
Overlaying these two conserved envelopes shows that when inhibitor atoms protrude 
beyond the substrate envelope and contact other PR residues, drug resistance occurs 
(Figure 4C).  Most drug resistant mutations in the active site do not contact the 
substrates, which prove that these primary mutations are caused by the inhibitor 
protruding beyond the substrate envelope.  The better inhibitors fit within this envelope, 
the less susceptible they are to drug resistance, since a mutation that affects the inhibitor 
would also affect cleavage of the majority of the substrates (Ali et al., 2010). 
 
 
Figure 4. (A) Substrate envelope of HIV-1 protease.  (B) The inhibitor envelope within 
the active site of HIV-1 protease.  (C) Overlay of the substrate envelope (blue) with the 
inhibitor envelope (red).  Residues that contact inhibitors due to their protrusion from the 
substrate envelope and confer drug resistance when mutated are labeled (Ali et al., 2010). 
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Fluorescent Resonance Energy Transfer (FRET) Assays 
In this project, in order to measure the enzymatic inhibitory constants (Ki’s) for 
different inhibitors, FRET assays were used.  These assays measure the increase in 
fluorescence over time.  The assay contains a natural substrate of HIV-1 which contains a 
fluorescent donor (EDANS) at the C-terminus and a quenching acceptor (DABCYL) at 
the N-terminus.  The substrate has the following sequence (Arg-Glu(EDANS)-Ser-Gln-
Asn-Tyr-Pro-Ile-Val-Gln Lys(DABCYL)-Arg) (Figure 5) where HIV-1 protease cleaves at 
the Tyr-Pro bond.  EDANS is excited at 340 nm and will only fluoresce if it is more than 
100 Å away from DABCYL.  So fluorescence will only occur if the substrate is cleaved 
by the protease.  Measuring the change of EDANS fluorescence intensity at 490 nm 
directly correlates with how much substrate has been cleaved (Matayoshi et al., 1990). 
 
                         Figure 5. Structure of the fluorogenic HIV-1 substrate (Matayoshi et al., 1990). 
 
From the data collected, initial velocities are plotted against the inhibitor concentrations 
and are fit by non-linear regression.  The Ki value is derived using the Morrison equation 
(Figure 6). 
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                                       Figure 6. The Morrison equation and its constants. 
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PROJECT PURPOSE 
 
The purpose of this project was to design novel HIV-1 protease inhibitors (PIs) 
that fit very well within the conserved substrate envelope, so that none of the functional 
groups would protrude out of the proposed envelope.  By focusing on the conserved 
envelop the drug should be much more potent, allowing it to bind to drug-resistant 
proteases.  The novel cores had six bonds in between two crucial carbonyls, which is 
similar to Darunavir and the substrates themselves, and the new cores also did not have 
an amide group linking the core to the P2’ group.  This allows the PI to have more 
degrees of freedom, making it easier to conform to the active site of the protease and 
many of its mutants.  The enzymatic kinetic evaluation on Darunavir and 11 of its 
analogues was performed to see whether the different functional groups bound tighter to 
drug-resistant proteases providing lower Ki’s.   
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METHODS 
Synthesis of (S)-ethyl 5-((S)-1-(tert-butoxycarbonylamino)-2-
phenylethyl)-2-oxotetrahydrofuran-3-carboxylate 
 
 
 
Epoxide 1 (20 g, 75.94 mmol) was mixed with diethylmalonate (12.68 mL, 83.53 mmol) 
and dissolved in EtOH (60 mL) at room temperature until the solution became 
homogeneous.  The mixture was cooled to 0 °C and NaOEt (5.68 g, 83.53 mmol) in 
EtOH (40 mL) was slowly added under dry nitrogen atmosphere, stirred for 30 min, 
warmed to room temperature, and stirred overnight.  Reaction was quenched by cooling 
the mixture to 5 °C and AcOH (10 mL) in EtOAc (90 ml) was slowly added.  EtOAc 
(200 mL) and a 25% aqueous solution of NaCl (200 mL) were added and layers 
separated.  The organic layer was washed with a 5% aqueous NaHCO3 solution (300 
mL), and then by a saturated aqueous NaCl solution (200 mL).  The extraction process 
was done once more with EtOAc (150 mL).  The combined organic extract was dried 
(Na2SO4), filtered, and evaporated under reduced pressure.  The residue was dissolved in 
t-butyl methyl ether (MTBE) (100 mL) and was evaporated to dryness once again.  The 
resulting crude off-white crystalline product was dissolved in MTBE (40 mL), filtered, 
and MTBE (15 mL) and n-heptane (90mL) were added and mixed at 60°C until 
homogeneous.  The product was allowed to crystallize overnight at 4°C.  The product 
was mixed, filtered, and the filter cake was washed with a mixture of MTBE and n-
heptane (1:9) (150 mL).  The solid was dried providing the pure off-white crystalline 
solid 2 (20.73 g, 72.3%). 
 
Synthesis of tert-butyl (S)-1-((S)-5-oxotetrahydrofuran-2-yl)-2-
phenylethylcarbamate 
 
 
 
To a solution of LiOH·H2O (5.56 g, 132.5 mmol) in water (100 mL) was added a solution 
of the ester 2 (10 g, 26.5 mmol) in 1, 2-dimethoxyethane (DME) (100 mL).  The reaction 
stirred at room temperature for 4 hours, then cooled to 0 °C, and a 10% aqueous solution 
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of citric acid (55 mL) was added to lower the pH to 6.  The mixture was partially 
evaporated under reduced pressure at room temperature, and a 2N HCl solution was used 
to get a pH of 3-4.  The resulting solution was stirred at room temperature for 2 hours and 
was extracted with EtOAc (3 x 300 mL) and once with CH2Cl2 (250 mL).  Combined 
organic extract was washed with a saturated aqueous NaCl solution (100 mL), dried 
(Na2SO4), filtered, and evaporated under reduced pressure to yield 10.1g of white foam.  
The resulting crude acid was dissolved in toluene (90 mL) and heated to 120 °C 
overnight.  The resulting solution was then evaporated under reduced pressure to yield a 
pale yellow gummy residue.  The residue was purified by flash column chromatography 
on silica gel, using an EtOAc-hexanes (3:7) mixture as eluent to provide the lactone 3 
(8.23 g, 87.1%) as an off-white solid. 
 
Synthesis of tert-butyl (S)-1-((2S,4R)-4-(3-methylbut-2-enyl)-5-
oxotetrahydrofuran-2-yl)-2-phenylethylcarbamate 
 
 
 
A 1.6 M solution of n-butyl lithium in THF (15 mL, 24.0 mmol) was added dropwise to a 
−78 °C solution of diisopropyl amine (3.47 mL, 24.53 mmol) in dry THF (24 mL) under 
dry nitrogen atmosphere, and stirred for 45 min.  Lactone 3 (3g, 9.81 mmol) in THF (10 
mL) was added drop-wise, and the enolate was allowed to form at this temperature for 45 
min.  A solution of 1-bromo-3-methylbut-2-ene (1.83 g, 12.26 mmol) in HMPA (10 mL) 
was added drop-wise to the reaction, which became very difficult to stir.  The reaction 
was left at −78°C for 30 min and then transferred to a −50°C bath.  The solution was 
maintained between −50 and −35°C for 2 hours and the reaction was quenched with a 
saturated aqueous solution of NH4Cl (15 mL).  After warming to room temperature, the 
organic layer was extracted with EtOAc (2 x 200 mL), which were then washed with a 
saturated NaCl aqueous solution (50 mL), dried (Na2SO4), filtered, and evaporated under 
reduced pressure.  The yellowish oil was purified by flash column chromatography on 
silica gel using an EtOAc in hexanes (15-20%) mixture as eluent to provide the ester 4 
(1.94 g, 52.8%) as a yellowish oil.   
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Synthesis of tert-butyl (S)-1-((2S,4R)-4-isopentyl-5-oxotetrahydrofuran-
2-yl)-2-phenylethylcarbamate 
 
 
 
 
Ester 4 (1.84 g, 5.18 mmol) was dissolved in an EtOAc-MeOH (95:5, 25 mL) mixture 
and a 10% Pd/C catalyst (0.400 g) was added and hydrogenated over night using 
balloons.  The reaction mixture was filtered through a pad of celite, the pad was washed 
with EtOAc, and the filtrate was evaporated under reduced pressure to yield an off-white 
solid which was purified by flash column chromatography on silica gel using an EtOAc 
in hexanes (30%) mixture as eluent to provide the lactone 5 (1.82 g, 93.4%) as a white 
solid.   
 
Synthesis of (2R,4S,5S)-5-(tert-butoxycarbonylamino)-4-(tert-
butyldimethylsilyloxy)-2-isopentyl-6-phenylhexanoic acid 
 
 
 
A 1M aqueous LiOH solution (16 mL) was slowly added at 4 °C to a solution of 
compound 5 (1.0 g, 2.66 mmol) in 1,2-DME (20 mL), and stirred overnight.  Citric acid 
was then added as to get a pH of 4 and the resulting solution was extracted with EtOAc (3 
x 150 mL).  The combined organic extract was washed with saturated aqueous NaCl 
solution (50 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure at  
20 °C.  The crude hydroxyl acid was dissolved in DMF (25 mL) and tert-
butyldimethylsilyl chloride (4.05g, 26.6 mmol) and imidazole (2.0 g, 29.3 mmol) were 
added to the solution and stirred for 36 hours.  The reaction mixture was treated with 
methanol (20 mL) and stirred for 8 hours, then evaporated under reduced pressure.  The 
reaction mixture was partitioned between a 10% aqueous citric acid solution (20 mL) and 
EtOAc (125 mL), and the aqueous layer was further extracted with EtOAc (125 mL).  
The combined organic extract was washed with a saturated aqueous NaCl solution (20 
mL), dried (Na2SO4), filtered, and evaporated under reduced pressure.  The resulting 
residue was purified by flash column chromatography on silica gel using a 2-3% 
methanol in CH2Cl2 mixture as an eluent to provide acid 6 (1.24 g, 91.8%) as an almost 
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clear gummy substance.  Analysis by NMR showed that some racemazation had 
occurred.  
 
Synthesis of tert-butyl (2S,3S,5R)-3-(tert-butyldimethylsilyloxy)-5-
((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-ylcarbamoyl)-8-methyl-1-
phenylnonan-2-ylcarbamate 
 
 
 
Acid 6 (0.40 g, 0.79 mmol) and (1S,2R)-(−)-cis-1-Amino-2-indanol (0.118 g, 0.79 mmol) 
were mixed in a 1:1 ratio of CH2Cl2:DMF (10 mL), cooled to 0 °C, and N-N-
diisopropylethylamine (DIEA) (0.31 g, 2.37 mmol) was slowly added.  Solid HATU 
(0.30 g, 0.79 mmol) was added in one portion after 15 minutes and left at 0 °C for 15 min 
before moving it to room temperature.  Reaction mixture was evaporated under reduced 
pressure, partitioned between water (20 mL) and EtOAc (125 mL), and the aqueous layer 
was extracted once more with EtOAc (125 mL).  The combined organic extract was 
washed with a saturated aqueous NaCl solution (20 mL), dried (Na2SO4), filtered, and 
evaporated under reduced pressure. 
 
Synthesis of (5S)-ethyl 5-((R)-1-((tert-butoxycarbonyl)amino)-2-
phenylethyl)-2-oxo-3-(4-(pyridin-2-yl)benzyl)tetrahydrofuran-3-
carboxylate 
 
 
 
Ester 2 (5.0 g, 13.25 mmol) and 2-(4-(bromomethyl)phenyl)pyridine (3.29 g, 13.25 
mmol) were mixed in EtOH (42 mL) for 15 min and cooled to 0 °C.  A solution of 
NaOEt (0.95 g, 13.9 mmol) in EtOH (8.5 mL) was slowly added, and the reaction 
mixture was left stirring at 4 °C overnight to yield lactone 8.   
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Synthesis of tert-butyl (R)-1-((2S,4S)-5-oxo-4-(4-(pyridin-2-
yl)benzyl)tetrahydrofuran-2-yl)-2-phenylethylcarbamate 
 
To the crude mixture containing lactone 8, LiOH·H2O (2.7 g, 64.29 mmol) was added 
portionwise over 5 min, and stirred for 2.5 hours at 0 °C.  AcOH (3.85 g, 68.57 mmol) 
was added and the reaction mixture was heated to 60 °C and left stirring overnight.  The 
suspension was cooled to room temperature and extracted with EtOAc (3 x 50 mL).  The 
combined organic extract was washed with a saturated NaCl aqueous solution (20 mL), 
dried (Na2SO4), filtered, and evaporated under reduced pressure.  The resulting residue 
was purified by flash column chromatography on silica gel using an EtOAc-hexanes (2:3) 
mixture as eluent, evaporated under reduced pressure, and was crystallized by dissolving 
in a MeCN-H2O (1:1) (50 mL) mixture at 75 °C for 1 hour and by slowly cooling the 
mixture to room temperature over a period of 2 hours.  The solid was filtered, and the 
filter cake was washed with a MeCN:H2O (1:1) (30 mL) mixture, n-heptane (20 mL) to 
give lactone 9 (2.0 g, 31.8%) as white fluffy crystals. 
Synthesis of tert-butyl (2S,3S,5S)-3-hydroxy-6-oxo-1-phenyl-5-(4-
(pyridin-2-yl)benzyl)decan-2-ylcarbamate 
 
 
To a solution of lactone 9 (0.166 g, 0.35 mmol) in dry THF (10 mL) at −78 °C and under 
dry nitrogen atmosphere, a 1.6 M solution of n-butyl Lithium in THF (1.18 mL, 1.89 
mmol) was slowly added and left stirring for 6 hours.  The reaction mixture was 
quenched with a saturated aqueous NH4Cl solution (5 mL) and extracted with EtOAc (2 x 
30 mL).  The combined organic extract was washed with a saturated aqueous NaCl 
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solution (15 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure.  The 
resulting residue was purified by flash column chromatography on silica gel using an 
EtOAc-hexanes (3:7) mixture as eluent to provide hydroxyketone 10 (0.120 g, 64.6%) as 
white crystals.  NMR analysis revealed that the product was a 4:1 mixture of the (5S:5R) 
isomers.  
 
Synthesis of tert-butyl (2S,3S,5S)-3-hydroxy-8-methyl-6-oxo-1-phenyl-5-
(4-(pyridin-2-yl)benzyl)nonan-2-ylcarbamate 
 
 
 
To a solution of lactone 9 (0.306 g, 0.646 mmol) in dry THF (15 mL) at −78 °C and 
under dry nitrogen atmosphere, a 1.4 M solution of sec-butyl Lithium in THF (2.3 mL, 
3.23 mmol) was slowly added and left stirring for 2 hours.  The reaction mixture was 
quenched with a saturated NH4Cl aqueous solution (10 mL) and extracted with EtOAc (2 
x 40 mL).  The combined organic extract was washed with a saturated aqueous NaCl 
solution (15 mL), dried (Na2SO4), filtered, and evaporated under reduced pressure.  The 
resulting residue was purified by flash column chromatography on silica gel using an 
EtOAc-hexanes (3:7) mixture as eluent to provide hydroxyketone 11 (0.008 g, 2.3%).   
 
 
HIV-1 Protease Inhibition Assays 
All HIV-1 protease inhibitor potencies were determined by fluorescent resonance 
energy transfer (FRET) assays.  The HIV-1 protease substrate, (Arg-Glu(EDANS)-Ser-
Gln-Asn-Tyr-Pro-Ile-Val-Gln Lys(DABCYL)-Arg) was purchased from Molecular 
Probes.  The electron donor (EDANS) and electron acceptor (DABCYL) were labeled at 
the two ends of the substrate.  Fluorescence measurements were completed using a 
fluorescence spectrophotometer (Photon Technology International) at 21 °C.  Excitation 
and emission wavelengths were set at 340 and 490 nm, respectively, and each reaction 
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was monitored for about 5 minutes.  Wild-type HIV-1 protease (Q7K) and its mutant 
variants were purified by desalted through PD-10 columns (Amersham Biosciences) in 
which sodium acetate (20 mM, pH 5) was used as the elution buffer.  The protease 
concentrations were around 50 nM as estimated by UV spectrophotometry at 280 nm.  
All inhibitors were dissolved in dimethylsulfoxide (DMSO) and diluted to their 
appropriate concentrations.  For all experiments, 40 μL of a 2 μM substrate were used in 
substrate buffer [0.1 M sodium acetate, 1 M sodium chloride, 1 mM ethylene-
diaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), 2% DMSO, and 1 mg/mL 
bovine serum albumin (BSA) with an adjusted pH of 4.7].  Protease (2 μL) and inhibitor 
(1 μL) or DMSO were mixed with 37 μL of buffer before addition of the substrate.  
Inhibitor binding dissociation constant (Ki) values were obtained by nonlinear regression 
fitting (GraFit 5, Erithacus software) to the plot of initial velocity as a function of 
inhibitor concentrations based on the Morrison equation.  The initial velocities were 
derived from the linear range of reaction curves.  Each of the inhibitors were measured in 
triplicate, and their averages were calculated.  The 12 drugs were measured against Wild-
Type (Q7K), and three multi-drug mutants of HIV-1 protease.  The three mutant 
proteases had the following mutations and were called: M1 (L10I, G48V, I54V, L63P, 
V82A); M2 (L10I, L63P, A71V, G73S, I84V, L90M); and M3 (I50V and A71V).   
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RESULTS 
 
 
The purpose of this project was to design novel HIV-1 protease inhibitors that fit 
very well within the conserved substrate envelope, thus minimizing their susceptibility to 
drug resistance.  Two novel cores were developed and synthesized.  To increase the 
degrees of freedom of the new inhibitors, they did not include an amide group linking the 
cores to the P2’ groups.  Enzymatic kinetic evaluations were performed on the most 
potent PI (DRV) and 11 new DRV analogues against WT and 3 mutant proteases. 
After various approaches to create the new cores, a final procedure was finally developed 
and optimized (Figure 7).  
 
                                Figure 7. General scheme of the procedure used to develop the new PI cores.  
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The two novel cores only vary at the third chiral center, with both their chirality and 
functional group (Figure 8). 
 
 
Figure 8. Structures of the two novel HIV-1 protease inhibitor cores, with the main 
scaffold cores shown in green. 
 
To measure inhibition activities for the 12 compounds, FRET assays were 
performed, and from the initial velocities for each concentration, a graph was obtained in 
which the Ki values were found by non-linear fitting.  The concentrations of drug used to 
measure the inhibitors ranged from 0 µM to 8 µM.  The 12 drugs were measured against 
Wild-Type (Q7K), and three multi-drug mutants of HIV-1 protease.  The three mutants 
had the following mutations and were called: M1 (L10I, G48V, I54V, L63P, V82A); M2 
(L10I, L63P, A71V, G73S, I84V, L90M); and M3 (I50V and A71V).  Four examples of 
these Ki graphs can be found below (Figures 9-12). 
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Figure 9. Inhibition curve for compound F with M1 mutant protease, 
gave a Ki of 0.001 nM. 
 
 
Figure 10. Inhibition curve for compound A with Q7K protease, gave a 
Ki of 0.001 nM. 
 
 
Figure 11. Inhibition curve for compound G with M2 mutant protease, 
gave a Ki of 0.001 nM. 
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Figure 12. Inhibition curve for compound A with M1 mutant protease, 
gave a Ki of 0.001 nM. 
 
The inhibition assays were performed in triplicate, and the averages and standard 
deviations are tabulated in Table 3.  The table shows that 7 compounds had Ki values that 
were in the same range as Darunavir, and 4 compounds that were much worse inhibitors.  
Compounds A, B, C, E, and F showed better inhibition than DRV for both M2 and M3 
proteases (right two columns in table).  Their values varied, but compounds C and F 
displayed the best inhibition to M2 protease, with Ki’s of 2 pM.  Compound C gave an 
average Ki of 1 pM for M3 protease.  None of the compounds had a lower Ki than DRV 
for Q7K and M1 proteases. Compounds H, I, J, and K gave Ki values that were much 
lower than DRV for all of the proteases.  Only compounds H and K gave Ki’s that were 
close to that of DRV, and were 48 and 55 pM respectively for the Q7K protease.  These 
values are in the pM range, but they are still 20-25 times higher than DRV.  Most of the 
Ki’s for compounds H through K were in the nM range, especially for the mutant groups. 
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Table 3. Average Ki for DRV and 11 new DRV analogues. 
Inhibitor  Q7K (nM)   M1 (nM)   M2 (nM)   M3 (nM)   
Darunavir   0.002±0.002   0.002±0.002   0.008±0.011   0.006±0.005  
Compound A   0.005±0.003   0.004±0.002   0.003±0.001   0.004±0.003  
Compound B   0.004±0.001   0.008±0.004   0.006±0.006   0.004±0.005  
Compound C   0.009±0.006   0.004±0.003   0.002±0.002   0.001±0.002  
Compound D   0.004±0.004   0.004±0.003   0.022±0.034   0.020±0.026  
Compound E   0.004±0.002   0.006±0.003   0.007±0.007   0.004±0.004  
Compound F   0.004±0.004   0.003±0.002   0.002±0.002   0.004±0.001  
Compound G   0.002±0.002   0.012±0.000   0.010±0.013   0.018±0.023  
Compound H   0.048±0.014   1.974±0.756   3.256±0.421   1.056±0.193  
Compound I   0.303±0.135   4.228±0.595   13.37±1.64   3.238±0.700  
Compound J   0.230±0.030   3.986±1.705   3.198±0.817   2.547±0.314  
Compound K   0.055±0.020   0.284±0.166   0.540±0.147   0.770±0.123  
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DISCUSSION 
 
Two new HIV-1 protease inhibitor cores were developed and are expected to fit 
well within the substrate envelope so that they should be less susceptible to encounter 
drug resistance.  Various Darunavir analogues have Ki values that are in the same range 
as DRV if not better.  So by changing different functional groups, the inhibitors can 
become better or worse. 
In order for a protease inhibitor to tightly bind to the protease, it must fit well 
within the substrate envelope and not protrude beyond it (Ali et al., 2010).  Darunavir fits 
well within the substrate envelope and is the most potent PI currently available 
(Anderson et al., 2009).  So by creating different DRV analogues, one can greatly 
enhance the binding affinity of the drug.  If the analogue protrudes out of the substrate 
envelope more than DRV, then the binding affinity will greatly diminish.   
Since the synthesis of two novel PI cores was developed, all that needs to be done 
now is add different functional groups to both sides of the cores.  There are many 
different options to choose from, and the groups that are more likely to fit within the 
substrate envelope will be the best candidates.  Computational analysis can greatly help 
choose which groups to add.  One can predict the most energetically favorable 
configuration of a compound, and by using a docking program one can predict how well 
a certain compound will bind to the HIV-1 protease.  After many new compounds are 
synthesized, FRET assays will be done as to see which compounds are the most potent.  
Then many other assays like solubility, toxicity, etc. are done as to see whether the new 
compounds have the potential to become new PIs.  In vivo studies must be conducted and 
crystallography will be done on any promising compounds. 
 32 
BIBLIOGRAPHY 
 
Ali A et al. (2010) Molecular basis for drug resistance in HIV-1 protease. Viruses. 2: 2509-2535.  
 
Anderson J et al. (2009) Viral Protease Inhibitors. Antiviral strategies.  Springer  Publishers.  
p. 85-90.  
 
Clavel F, Hance A (2004) HIV Drug Resistance. The New England journal of medicine 350: 
1023-1035.  
 
Frankel AD, Young JA (1998) HIV: Fifteen proteins and an RNA.  Annual Reviews in 
Biochemistry 67: 1-25. 
 
Freed EO (1998) HIV-1 Gag Protein: Diverse Functions in the Virus Life Cycle. Virology 251: 1-
15.  
 
King NM et al. (2004) Combating Susceptibility to Drug Resistance: Lessons from HIV-1 
Protease. Chemistry & biology 11: 1333-1338.  
 
Kozak SL et al. (1997). CD4, CXCR-4, and CCR-5 dependencies for infections by primary 
patient and laboratory-adapted isolates of human immunodeficiency virus type 1. Journal of 
Virology 71: 873-882.  
 
Matayoshi E et al. (1990) Novel fluorogenic substrates for assaying retroviral proteases by 
resonance energy transfer. Science 247: 954-958. 
 
Mehellou Y, De Clercq, E (2010) Twenty-six years of anti-HIV drug discovery: Where do we 
stand and where do we go? Journal of Medicinal Chemistry 53: 521-538. 
 
Nalam M, Schiffer C (2008) New approaches to HIV protease inhibitor drug design II: testing the 
substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Current 
Opinion in HIV and AIDS  3: 642-646.  
 
NIAID’s http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/biology.aspx 
 
Perez M et al. (2010) Substrate recognition in HIV-1 protease: A computational study. Journal of 
Physical Chemistry 114: 2525-2532. 
 
Pornillos O et al. (2011) Atomic-level modeling of the HIV capsid. Nature 469: 424-427. 
 
(UNAIDS). Joint United Nations Programme on HIV/AIDS. Report for 2009. 
 
Warnke D, Barreto J (2007) Antiretroviral Drugs. Journal of Clinical Pharmacology 47: 1570-
1579.  
 
Weiss RA, (1993) How does HIV cause AIDS?  Science 260: 1273-1279. 
 
